This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ430DU_L.jpg
Eylea, a key growth driver for the drugmaker, has been facing competition from Roche’s Vabysmo since the rival secured U.S. approval last year.
The drug recorded sales of $2.28 billion in the quarter, missing expectations of $2.43 billion, according to an average of six analysts’ estimates polled by Refinitiv.
The company has also been leaning on its anti-inflammatory drug Dupixent – a treatment currently approved for five indications including asthma and atopic dermatitis, or eczema.
Quarterly sales of Dupixent, recorded by Regeneron (NASDAQ:REGN)’s partner Sanofi (NASDAQ:SNY), rose about 37% to $2.49 billion, above expectations of $2.38 billion.
Regeneron’s total revenue of $3.16 billion beat estimates of $3 billion.
Excluding items, the company reported a profit of $10.09 per share, above estimates of $9.56.
